Medicare shelled out $5.7 billion on Ozempic and other similar diabetes drugs in 2022, up from $57 million in 2018, according to a new KFF analysis.
Medicare shelled out $5.7 billion on Ozempic and other similar diabetes drugs in 2022, up from $57 million in 2018, according to a new KFF analysis.
